Abstract
Behçet disease (BD) is an inflammatory, multisystemic vasculitis of unknown etiopathogenesis. However, innate and adaptive immune system involvement and immune-mediated networks play a vital role in the inflammatory cascade. Indoleamine 2,3-dioxygenase 1 (IDO1) is activated in chronic inflammatory states and catalyzes the first and rate-limiting step of tryptophan (TRP) metabolism along the kynurenine pathway (KP). The study aimed to measure KP metabolites levels in patients with BD and investigate the relationship between disease activity and clinical findings with these metabolites. The study included 120 patients with BD and 120 healthy volunteers. Serum TRP, kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), and quinolinic acid (QUIN) levels were measured with the tandem mass spectrometric method. Demographic data, clinical manifestations, and disease activity score (BDCAF) were recorded. Serum KYN, KYNA, 3HK, 3HAA, QUIN levels, and KYN/TRP ratio were higher (p < 0.05) in patients with BD compared to the control group, while TRP levels were lower (p < 0.05). KYN/TRP ratio and QUIN levels were significantly higher in the presence of neuro-Behçet, while serum KYN levels were significantly higher in the presence of arthritis (p < 0.05). In addition, serum QUIN levels were significantly higher in the presence of thrombosis (p < 0.05). BDCAF score positively correlated with KYN/TRP ratio. Our findings showed that serum KP metabolite levels were elevated in patients with BD, and there is a relationship between these metabolites with disease activity, clinical findings, and inflammatory burden.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aktaş-Çetin E, Cosan F, Cefle A, Deniz G (2014) IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behçet’s disease. Mod Rheumatol/japan Rheum Assoc. https://doi.org/10.3109/14397595.2013.879414
Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632. https://doi.org/10.1111/1346-8138.13381
Badawy AA (2017) Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 10:1178646917691938. https://doi.org/10.1177/1178646917691938
Badawy AA (2018) Hypothesis kynurenic and quinolinic acids: the main players of the kynurenine pathway and opponents in inflammatory disease. Med Hypotheses 118:129–138. https://doi.org/10.1016/j.mehy.2018.06.021
Badawy AA, Guillemin G (2019) The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res 12:1178646919868978. https://doi.org/10.1177/1178646919868978
Bansal Y, Singh R, Parhar I, Kuhad A, Soga T (2019) Quinolinic acid and nuclear factor erythroid 2-related factor 2 in depression: role in neuroprogression. Front Pharmacol 10:452. https://doi.org/10.3389/fphar.2019.00452
Colín-González AL, Maldonado PD, Santamaría A (2013) 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 34:189–204. https://doi.org/10.1016/j.neuro.2012.11.007
Coskun E, Alidris A, Temel M, Akbayram S, Hizli S (2019) Plateletcrit: a possible biomarker of inflammation in hepatitis A infection. Niger J Clin Pract 22:727–730. https://doi.org/10.4103/njcp.njcp_331_18
Coutinho I, Silva D, Ferreira I, Grima B, Lisboa M, Bernardo M, Prieto I (2017) Behçet Disease: our Experience. Rev Bras Oftalmol 76(4):210–212. https://doi.org/10.5935/0034-7280.20170043
Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM (2009) The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 113(11):2394–2401. https://doi.org/10.1182/blood-2008-07-144485
Eisa NH, Reddy SV, Elmansi AM, Kondrikova G, Kondrikov D, Shi XM, Novince CM, Hamrick MW, McGee-Lawrence ME, Isales CM, Fulzele S, Hill WD (2020) Kynurenine promotes RANKL-induced osteoclastogenesis in vitro by activating the aryl hydrocarbon receptor pathway. Int J Mol Sci. https://doi.org/10.3390/ijms21217931
Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, Hatemi G (2017) Behçet’s syndrome: providing integrated care. J Multidiscip Healthc 10:309–319. https://doi.org/10.2147/jmdh.S93681
Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E (2017) An elevated pro-inflammatory cytokines profile in Behcet’s disease: a multiplex analysis. Immunol Lett 186:46–51. https://doi.org/10.1016/j.imlet.2016.12.001
Hasan MS, Bergmeier L, Petrushkin H, Fortune F (2015) Gamma Delta ( γδ ) T Cells and their involvement in Behçet’s disease. J Immunol Res. https://doi.org/10.1155/2015/705831
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
Işık M, Şahin H, Hüseyin E (2014) New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. Eur J Rheumatol 1(4):144–146. https://doi.org/10.5152/eurjrheumatol.2014.140023
Joisten N, Schumann M, Schenk A, Walzik D, Freitag N, Knoop A, Thevis M, Bloch W, Zimmer P (2020) Acute hypertrophic but not maximal strength loading transiently enhances the kynurenine pathway towards kynurenic acid. Eur J Appl Physiol. https://doi.org/10.1007/s00421-020-04375-9
Jones SP, Franco NF, Varney B, Sundaram G, Brown DA, de Bie J, Lim CK, Guillemin GJ, Brew BJ (2015) Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. PLoS ONE 10(6):0131389. https://doi.org/10.1371/journal.pone.0131389
Jonescheit H, Oberg H-H, Gonnermann D, Hermes M, Sulaj V, Peters C, Kabelitz D, Wesch D (2020) Influence of Indoleamine-2,3-Dioxygenase and Its metabolite kynurenine on γδ T Cell cytotoxicity against ductal pancreatic adenocarcinoma cells. Cells 9(5):1140. https://doi.org/10.3390/cells9051140
Jovanovic F, Candido KD, Knezevic NN (2020) The role of the kynurenine signaling pathway in different chronic pain conditions and potential use of therapeutic agents. Int J Mol Sci. https://doi.org/10.3390/ijms21176045
Kawasaki T, Kawai T (2014) Toll-like receptor signaling pathways. Front Immunol. https://doi.org/10.3389/fimmu.2014.00461
Lanser L, Kink P, Egger EM, Willenbacher W, Fuchs D, Weiss G, Kurz K (2020) Inflammation-induced tryptophan breakdown is related With anemia, fatigue, and depression in cancer. Front Immunol 11:249–249. https://doi.org/10.3389/fimmu.2020.00249
Leccese P, Alpsoy E (2019) Behçet’s Disease: an overview of etiopathogenesis. Front Immunol 10:1067. https://doi.org/10.3389/fimmu.2019.01067
Leszczyńska A, Misztal T, Marcińczyk N, Kamiński T, Kramkowski K, Chabielska E, Pawlak D (2019) Effect of quinolinic acid-a uremic toxin from tryptophan metabolism-on hemostatic profile in rat and mouse thrombosis models. Adv Med Sci 64(2):370–380. https://doi.org/10.1016/j.advms.2019.05.003
Moffett JR, Namboodiri MA (2003) Tryptophan and the immune response. Immunol Cell Biol 81(4):247–265. https://doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x
Moffett JR, Espey MG, Namboodiri MA (1994) Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res 278(3):461–469. https://doi.org/10.1007/bf00331364
Moffett JR, Arun P, Puthillathu N, Vengilote R, Ives JA, Badawy AA, Namboodiri AM (2020) Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD(+) synthesis during inflammation and infection. Front Immunol 11:31. https://doi.org/10.3389/fimmu.2020.00031
Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D (2021) Role of kynurenine pathway in oxidative stress during neurodegenerative disorders. Cells. https://doi.org/10.3390/cells10071603
Mumcu G, Alibaz Öner F, Ergun T, Direskeneli RH (2020) Decreasing incidence and severity of Behçet’s disease: a changing trend in epidemiological spectrum possibly associated with oral health. Turk J Med Sci 50:1587–1590. https://doi.org/10.3906/sag-2003-147
Muneer A (2020) Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin Psychopharmacol Neurosci 18(4):507–526. https://doi.org/10.9758/cpn.2020.18.4.507
Orhan F, Bhat M, Sandberg K, Ståhl S, Piehl F, Svensson C, Erhardt S, Schwieler L (2016) Tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor stimulation in peripheral monocytes. Scand J Immunol 84(5):262–271. https://doi.org/10.1111/sji.12479
Pallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, Volpi C, Grohmann U (2021) Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. Febs j. https://doi.org/10.1111/febs.16086
Patel D, Potter M, Anaya JM, McGee-Lawrence ME, Hamrick MW, Hill WD, Isales CM, Fulzele S (2021) Kynurenine induces an age-related phenotype in bone marrow stromal cells. Mech Ageing Dev 195:111464. https://doi.org/10.1016/j.mad.2021.111464
Pawlak K, Brzosko S, Mysliwiec M, Pawlak D (2009a) Kynurenine, quinolinic acid–the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 204(2):561–566. https://doi.org/10.1016/j.atherosclerosis.2008.10.002
Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D (2009b) Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res 124(4):452–457. https://doi.org/10.1016/j.thromres.2009.04.011
Pawlak K, Mysliwiec M, Pawlak D (2009c) Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 102(1):49–55. https://doi.org/10.1160/th08-10-0696
Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D (2010a) Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Am J Med Sci 339(1):5–9. https://doi.org/10.1097/MAJ.0b013e3181b922a4
Pawlak K, Mysliwiec M, Pawlak D (2010b) Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res 125(2):e40-45. https://doi.org/10.1016/j.thromres.2009.08.009
Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A (2012) Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5:1–8. https://doi.org/10.4137/ijtr.S8158
Pérez-González A, Alvarez-Idaboy J, Galano A (2017) Dual antioxidant/Pro-oxidant behavior of the tryptophan metabolite 3-hydroxyanthranilic acid: a theoretical investigation on reaction mechanisms and kinetics. New J Chem. https://doi.org/10.1039/C6NJ03980D
Rokutanda R, Kishimoto M, Okada M (2014) Update on the diagnosis and management of Behçet’s disease. Open Access Rheumatol 7:1–8. https://doi.org/10.2147/OARRR.S46644
Savitz J (2020) The kynurenine pathway: a finger in every pie. Mol Psychiatry 25(1):131–147. https://doi.org/10.1038/s41380-019-0414-4
Sun F, Cao H, Wang F, Cao G (2020) Behçet’s disease with invasive pulmonary aspergillosis and Aspergillus auriculatus infection: a case report. Medicine 99:18938. https://doi.org/10.1097/MD.0000000000018938
Tang K, Wu Y-H, Song Y, Yu B (2021) Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol 14(1):68. https://doi.org/10.1186/s13045-021-01080-8
Tong Q, Song J, Yang G, Fan L, Xiong W, Fang J (2018) Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. https://doi.org/10.1002/bmc.4156
Tong B, Liu X, Xiao J, Su G (2019) Immunopathogenesis of Behcet’s Disease. Front Immunol 10:665–665. https://doi.org/10.3389/fimmu.2019.00665
Türkçüoğlu P, Arat YO, Kan E, Kan EK, Chaudhry IA, Koca S, Çeliker Ü, İlhan N (2016) Association of disease activity with serum and tear IL-2 levels in Behçet disease. Ocul Immunol Inflamm 24(3):313–318. https://doi.org/10.3109/09273948.2014.1003661
Wirthgen E, Hoeflich A, Rebl A, Günther J (2018) Kynurenic acid: the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front Immunol. https://doi.org/10.3389/fimmu.2017.01957
Zaher SS, Germain C, Fu H, Larkin DFP, George AJT (2011) 3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol vis Sci 52(5):2640–2648. https://doi.org/10.1167/iovs.10-5793
Acknowledgements
The authors would like to thank Selcuk University for this study.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
Each named author has contributed to conducting the research and drafting the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
This study was performed according to guidelines established by the 2013 Helsinki Declaration, and the protocol was approved by the Selcuk University Faculty of Medicine Ethics Committee (Number: 2020/226, Date: 03.06.2020).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
All the authors have read and approved the manuscript.
Additional information
Handling editor: S. S. Gross.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Eryavuz Onmaz, D., Tezcan, D., Abusoglu, S. et al. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease. Amino Acids 54, 877–887 (2022). https://doi.org/10.1007/s00726-022-03170-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-022-03170-4